by
Brendon Nafziger, DOTmed News Associate Editor | July 02, 2012
Ion Beam Applications S.A.'s newly spun-off radiopharmaceutical wing IBA Molecular has inked a five-year deal with group purchasing organization Novation LLC to supply its member health care facilities with PET radiotracers.
Under the deal, announced Monday, IBA Molecular will supply imaging agents, including 18-Fluorodeoxyglucose, as well as provide educational and training services. The contract took effect July 1. Terms of the deal weren't disclosed.
IBA Molecular has 54 PET isotope facilities in Europe, North America and Asia. It also delivers agents for SPECT imaging worldwide.
Ad Statistics
Times Displayed: 3341
Times Visited: 6 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
SK Capital Partners holds a controlling stake in IBA Molecular, which was spun off from its Belgian parent company, which retains a minority stake, in April.
